Mount Sinai Health system receives $8.5 million NIH grant renewal to advance research on long-term outcomes in children with congenital heart disease
Grant and Award Announcement
Updates every hour. Last Updated: 28-May-2026 19:15 ET (28-May-2026 23:15 GMT/UTC)
The National Institutes of Health has awarded the Icahn School of Medicine at Mount Sinai an $8.5 million renewal grant to continue groundbreaking work aimed at understanding and improving long-term outcomes for children with congenital heart disease—the most common type of birth defect in the United States.
A research team led by the Institute for Bioengineering of Catalonia (IBEC) has developed an innovative, portable, smartphone-based system for assessing sleep apnoea in individuals with different health conditions. The study, published in IEEE Transactions on Neural Systems and Rehabilitation Engineering, in collaboration with the Guttmann Institute, shows that this technology can facilitate the early detection of a common but underdiagnosed disorder, which negatively impacts the recovery and rehabilitation of patients who have suffered a stroke.
Giant DNA viruses that infect eukaryotic cells are thought to have played a role in the evolution of life, according to the nuclear virus origin hypothesis. Now, the discovery of a new giant DNA virus in Japan that infects vermamoeba further supports this idea. Named ushikuvirus, it joins a growing number of such viruses being discovered worldwide, suggesting that ancient viruses may have contributed to the evolution and diversity of eukaryotic cells.
A Korea University research team has discovered that pitavastatin, a widely used lipid-lowering drug, can directly inhibit the Mcl-1 protein—an essential survival factor for therapy-resistant triple-negative breast cancer (TNBC). By blocking Mcl-1–dependent mitochondrial protection, pitavastatin eliminates cancer stem-like cells, suppresses metastasis, and restores paclitaxel sensitivity in preclinical models. This repurposed drug may offer a safer, faster-to-deploy therapeutic strategy for patients with aggressive or chemotherapy-refractory TNBC.
Ventilatory ratio (VR) is a simple bedside index reflecting pulmonary dead space and is associated with outcomes in acute respiratory distress syndrome (ARDS). This study developed and validated separate 30-day mortality prediction models for high and low VR subgroups using multicenter critical care databases. Subgroup-specific models demonstrated superior predictive performance compared with cross-applied models, highlighting the importance of VR-based stratification for improving prognostic accuracy and supporting more individualized ARDS management strategies.